DGAP-News: Atriva receives FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections
Retrieved on:
Monday, January 10, 2022
Safety, CDC, Viral hemorrhagic fever, RSV, RNP, Risk, Macrophage inflammatory protein, Severe acute respiratory syndrome coronavirus 2, Viral load, Death, Orthohantavirus, CSO, Patient, Orthornavirae, ODD, Chemokine, Gene expression, Category, Orphan drug, Hantavirus pulmonary syndrome, RNA, III, Food, Patent, ECDC, Therapy, Degenerative disease, Cell, Company, Cytoplasm, Cytokine, Human, Vaccine, CEO, COVID-19, FDA, Disease, Gesellschaft mit beschränkter Haftung, Orphan, Fatality, Hantavirus hemorrhagic fever with renal syndrome, HPS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MEK, Pharmaceutical industry, HFRS, zapnometinib's mode of action with dual effect, Atriva Therapeutics GmbH, ZAPNOMETINIB'S MODE OF ACTION WITH DUAL EFFECT, ATRIVA THERAPEUTICS GMBH
"Antiviral efficacy of zapnometinib against hantavirus has been previously proven in vitro in an academic collaboration.
Key Points:
- "Antiviral efficacy of zapnometinib against hantavirus has been previously proven in vitro in an academic collaboration.
- Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, commented: "The Orphan Drug Designation we received for our lead drug candidate zapnometinib is an important milestone towards addressing the urgent needs of patients infected with hantavirus.
- [1]
The FDA may grant Orphan Drug Designation (ODD) to support the development and evaluation of new treatments for rare diseases. - [11]
The Atriva lead product zapnometinib (ATR-002) is developed specifically to treat diseases such as influenza and COVID-19, caused by RNA viruses.